LivaNova PLC has initiated a process with the U.S. Centers for Medicare and Medicaid Services $(CMS)$ to reconsider national Medicare coverage for its VNS Therapy™ in unipolar patients with treatment-resistant depression $(TRD.UK)$. This development marks a significant step in LivaNova's efforts to secure broader access to this therapy. The reconsideration request is backed by strong 24-month clinical outcomes from the RECOVER study, demonstrating the durability and effectiveness of VNS Therapy. Five critical articles analyzing primary and select secondary endpoint data from the study have been published or accepted by peer-reviewed journals, fulfilling the Coverage with Evidence Development (CED) requirement for publicly accessible results. This comprehensive data presentation aims to support the company's submission for coverage reconsideration by CMS.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。